Antigenic Conversion of Tumor Cells

Antigenic conversion of tumor cells is the process of changing the antigenic structure of tumor cells, which leads to a change in their immunogenicity and the response of the immune system to them. This process can be caused by various factors such as chemotherapy, radiation therapy, immunotherapy, as well as genetic mutations in tumor cells.

Antigenic conversion can be artificial when it is induced specifically using various methods, such as the introduction of antigens or the use of antibodies. Artificial antigen conversion makes it possible to create more effective cancer treatments because it allows the immune system to recognize and attack tumor cells specifically.

However, antigen conversion can also occur naturally when tumor cells are altered by various factors such as stress, radiation or chemotherapy. Natural antigenic conversion can lead to a decrease in the immunogenicity of tumor cells and a decrease in their ability to generate an immune response.

Overall, antigenic conversion is a complex process that can have both positive and negative consequences for patients. However, understanding the mechanisms of antigenic conversion and its role in cancer treatment may help develop more effective methods to combat this disease.

Antigenic conversion of tumor cells is the process of modifying tumor cells in order to prevent the development of graft-versus-host disease and improve the interaction between the donor and the recipient. It is based on changing the antigenic profile of the tumor by introducing allodor or autodonor antigens into its tissue.

The main goal of antigenic conversion is to reduce the intensity of the graft-versus-host reaction associated with the formation of transplantation antigens on the surface of tumor cells (allogeneic tumor), or on the recipient’s own T cells (autogenous tumor). The allo/autogenesis process does not reduce the risk of rejection. This is due to the fact that the formation of a tumor component of an allo- or autotransplanted organ is incompatible with the obsolete normal elements of the donor organ. Therefore, such a component requires the development of adaptation. At the same time, the implementation of acquired immune reactions triggers de